# The impact of diabetes duration and glycemic control on ejection fraction in heart failure patients

**Authors:** Omer Dogan, Hasan Ali Barman, Ebru Serin, Abdullah Omer Ebeoglu, Adem Atici, Ridvan Turkmen, Ibrahim Temel, Isilay Kok, Omer Gok, Ipek Aydin, Pelinsu Elif Ozkan, Ali Nayir, Melike Kaya, Cem Kurt, Aylin Altun, Kursad Oz, Isil Uzunhasan, Murat Kazım Ersanli, Rasim Enar, Sait Mesut Dogan

PMC · DOI: 10.1007/s00592-025-02519-x · Acta Diabetologica · 2025-05-07

## TL;DR

This study finds that longer diabetes duration, but not poor glycemic control, is linked to reduced heart ejection fraction in patients with heart failure and type 2 diabetes.

## Contribution

The study identifies diabetes duration as an independent predictor of reduced ejection fraction in heart failure patients with T2DM.

## Key findings

- Diabetes duration was significantly longer in patients with reduced ejection fraction (HFrEF) compared to those with preserved or mid-range ejection fraction.
- Multivariable analysis showed diabetes duration, hypertension, and use of oral antidiabetic agents as independent predictors of reduced ejection fraction.
- Poor glycemic control was not an independent predictor of reduced ejection fraction despite being more common in HFrEF patients.

## Abstract

The potential effects of diabetes duration and glycemic control on ejection fraction (EF) in patients with heart failure (HF) remain unclear. We investigated the impact of diabetes duration and glycemic control on ejection fraction (EF), alongside other risk factors, in HF patients with type 2 diabetes mellitus (T2DM).

This single-center retrospective study included 1265 patients who were admitted and discharged with a diagnosis of HF between January 2010 and January 2022, all of whom had a known diagnosis of T2DM prior to admission. The patients included in the study were divided into two groups: those with heart failure and reduced ejection fraction (HFrEF, EF ≤ 40%) and those with or mid-range or preserved ejection fraction (HFmrEF + HFpEF, EF > 40%).

Among the 1265 patients, 697 had HFrEF. The duration of diabetes was significantly longer (13 vs. 7 years, p < 0.001) and HbA1c levels were higher (8.4 ± 1.6% vs. 7.7 ± 1.5%, p < 0.001) in the HFrEF group. Multivariable analysis identified diabetes duration (OR 2.23, p < 0.001), hypertension (OR:6.62, p < 0.001), and the use of oral antidiabetic agents (OR 0.74, p = 0.042) as independent predictors of reduced EF. Prolonged diabetes duration was associated with a reduction in EF (AUC = 0.780, p < 0.001). Conversely, although glycemic control was poorer in the HFrEF group, it was not an independent predictor of EF.

Prolonged diabetes duration significantly reduces EF, among HF patients with T2DM, independent of glycemic control and other risk factors. While poor glycemic control was more prevalent in HFrEF patients, it did not independently affect EF.

## Linked entities

- **Diseases:** diabetes mellitus, type 2 (MONDO:0005148), heart failure (MONDO:0005252)

## Full-text entities

- **Diseases:** diabetes (MESH:D003920), in EF (MESH:D054144), T2DM (MESH:D003924), HF (MESH:D006333), hypertension (MESH:D006973), HFrEF (MESH:D054143)
- **Chemicals:** oral antidiabetic agents (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12578722/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12578722/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12578722/full.md

---
Source: https://tomesphere.com/paper/PMC12578722